Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emavusertib - Aurigene Oncology/Curis

Next Previous
X
Search
Drug Profile

Emavusertib - Aurigene Oncology/Curis

Alternative Names: AU 4948; CA 4948

Latest Information Update: 21 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Curis; University of Leipzig
  • Class Amides; Amines; Antianaemics; Antineoplastics; Antirheumatics; Morpholines; Oxazoles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Clk dual-specificity kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; IRAK4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia
  • Phase I/II Acute myeloid leukaemia; Malignant melanoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I Gastric cancer; Oesophageal cancer
  • Preclinical Adenocarcinoma; Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2024 University of Leipzig in collaboration with Curis terminates a phase II LUCAS trial in Anaemia in Germany (PO), prematurely according to the trial protocol (NCT05178342) (EudraCT2020-003986-20)
  • 31 Jul 2024 Emavusertib - Aurigene Oncology/Curis receives Orphan Drug status for Non-Hodgkin's lymphoma in European Union
  • 13 Jun 2024 Efficacy results from a phase I/IIa TakeAim Leukemia trial for Acute myeloid leukaemia and Myelodysplastic syndromes at the 29th Congress of the European Haematology Association (EHA-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top